The University of Glasgow uses cookies for analytics. Find out more about our Privacy policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.
Analytical cookies help us improve our website. We use Google Analytics. All data is anonymised.
Hotjar and Clarity help us to understand our users’ behaviour by visually representing their clicks, taps and scrolling. All data is anonymised.
telephone:
01413303103
email:
Karin.Williams@glasgow.ac.uk
Derby, S. et al. (2024) Concurrent olaparib and radiotherapy in elderly patients with newly diagnosed glioblastoma: the phase I dose escalation PARADIGM trial. International Journal of Radiation Oncology, Biology, Physics, (doi: 10.1016/j.ijrobp.2024.01.011) (PMID:38211641) (In Press)
Jackson, M. R. et al. (2022) Low-dose lung radiotherapy for COVID-19 lung disease: a preclinical efficacy study in a bleomycin model of pneumonitis. International Journal of Radiation Oncology, Biology, Physics, 112(1), pp. 197-211. (doi: 10.1016/j.ijrobp.2021.08.029) (PMID:34478832) (PMCID:PMC8406661)
Hanna, C. et al. (2020) Pharmacokinetics, safety and tolerability of olaparib and temozolomide for recurrent glioblastoma: results of the phase I OPARATIC trial. Neuro-Oncology, 22(12), pp. 1840-1850. (doi: 10.1093/neuonc/noaa104) (PMID:32347934) (PMCID:PMC7746945)
Derby, S. et al. (2024) Concurrent olaparib and radiotherapy in elderly patients with newly diagnosed glioblastoma: the phase I dose escalation PARADIGM trial. International Journal of Radiation Oncology, Biology, Physics, (doi: 10.1016/j.ijrobp.2024.01.011) (PMID:38211641) (In Press)
Jackson, M. R. et al. (2022) Low-dose lung radiotherapy for COVID-19 lung disease: a preclinical efficacy study in a bleomycin model of pneumonitis. International Journal of Radiation Oncology, Biology, Physics, 112(1), pp. 197-211. (doi: 10.1016/j.ijrobp.2021.08.029) (PMID:34478832) (PMCID:PMC8406661)
Hanna, C. et al. (2020) Pharmacokinetics, safety and tolerability of olaparib and temozolomide for recurrent glioblastoma: results of the phase I OPARATIC trial. Neuro-Oncology, 22(12), pp. 1840-1850. (doi: 10.1093/neuonc/noaa104) (PMID:32347934) (PMCID:PMC7746945)